Colorectal Adenoma, Stage 0 Colorectal Cancer AJCC v8, Stage I Colorectal Cancer AJCC v8, Stage IIA Colorectal Cancer AJCC v8, Stage IIB Colorectal Cancer AJCC v8, Stage IIC Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8
Conditions
Brief summary
This phase II trial studies the how well linaclotide works in treating patients with stages 0-3 colorectal cancer. Linaclotide is a very small protein that binds to receptors on intestinal cells and makes them secrete water and salt.
Detailed description
PRIMARY OBJECTIVES: I. To determine whether, compared to placebo, linaclotide administered as a single oral daily dose x 7 days, induces a pharmacodynamics (PD) effect on cGMP levels, based on biopsy samples of adenomas or resected colorectal adenocarcinomas. SECONDARY OBJECTIVES: I. To compare Ki-67, guanylin levels and GUCY2C expression in adenomas and cancers versus normal tissue after exposure to linaclotide or placebo. II. To confirm the safety and tolerability of linaclotide in sporadic adenoma and cancer patients. TRANSLATIONAL OBJECTIVE: I. To assess the pharmacodynamic effect of linaclotide on pathway-specific biomarkers relevant to GUCY2C signaling (i.e. VASP phosphorylation), markers of mutant APC-beta-catenin signaling (beta-catenin levels, beta-catenin nuclear localization, axin levels, c-Myc levels, guanylin levels, PCNA expression), based on adenoma/cancer and normal mucosa biopsy samples obtained by endoscopy following linaclotide or placebo exposure. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive linaclotide orally (PO) daily on days 1-7 and undergo standard of care colonoscopy or surgery on day 7. ARM II. Patients receive placebo PO QD on days 1-7 and undergo standard of care colonoscopy or surgery on day 7. After completion of study treatment, patients are followed up at day 14.
Interventions
DRUGLinaclotide
Given PO
OTHERPlacebo
Given PO
Sponsors
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
United States Department of Defense
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* History of 1 or more sporadic colorectal adenoma on previous endoscopy (adenoma cohort) or stage 0-3 biopsy proven colorectal cancer (CRC) (colorectal cancer cohort) who are scheduled for a surgical procedure * Ability to understand and willingness to sign a written informed consent document and follow study procedures * Ability to swallow capsules without difficulty * Ability to maintain pill diaries * Willingness to employ adequate contraception for men and women of childbearing potential for the duration of the study. Acceptable methods include double barrier methods, intrauterine device (IUD), postmenopausal status, and/or documentation of surgical sterilization * Participants must have no chronic, clinically severe health issues which, in the opinion of their physician or the research team, could preclude trial activities including the one week drug exposure phase
Exclusion criteria
* History of gastroparesis * History of celiac disease * Inflammatory bowel disease (Crohn's disease, ulcerative colitis) * Microscopic colitis, including collagenous colitis * Has taken linaclotide within 30 days prior to consent * Any malignancy except colorectal cancer or any active radiotherapy or cytotoxic chemotherapy within the last 6 months of baseline. Participants with a history of basal cell or squamous cell skin cancer may be enrolled at the discretion of the investigator * Participants may not be receiving any other investigational agents, or be active participants in any clinical trials. If participants previously participated in a clinical trial, a 30 day washout period for the investigational drug is needed before the participant can be considered for this study * History of allergic reactions attributed to compounds of similar chemical or biologic composition to linaclotide * Uncontrolled current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Pregnant or lactating women * History of bleeding/coagulation problems. Concurrent use of nonsteroidal anti-inflammatory drugs (NSAIDs) including aspirin is acceptable * Any medical condition judged by the investigator to constitute a risk to safe participation * At risk for obstructing or near-obstructing mechanical gastrointestinal obstruction * Chronic use of anti-coagulants or non-NSAID anti-platelet agents will serve as an exclusion only when such medications cannot be safely discontinued before study related endoscopy or surgery
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacodynamics effect on cGMP levels | Up to 2 years, plus an additional 12 months for primary analysis | Will compare cGMP levels in adenomas between study arms using a two-sample t-test (alpha=.05; two-sided) or Wilcoxon rank sum test. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of adverse events (AEs) | From the time of first dose of linaclotide or placebo until resolution, if related to linaclotide, or through 30 days after occurrence | All participants will be evaluated for toxicity. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will be used to summarize adverse events associated with linaclotide. |
| Ki-67 expression | Up to 2 years | Wilcoxon rank sum test will be used to compare Ki-67 expression in adenomas across arms. |
| GUCY2C expression | Up to 2 years | Wilcoxon rank sum and Fisher's exact tests will be used to compare GUCY2C expression between study arms. |
| Guanylin levels | Up to 2 years | Wilcoxon rank sum and Fisher's exact tests will be used to compare guanylin levels between study arms. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORScott Waldman, MD
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Outcome results
None listed